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Background: Inclusion body myositis (IBM) is a slowly progressive inflammatory myopathy of the elderly that does
not show significant clinical improvement in response to steroid therapy. Distinguishing IBM from polymyositis (PM)
is clinically important since PM is steroid-responsive; however, the two conditions can show substantial histologic
overlap.
Results: We performed quantitative immunohistochemistry for (1) autophagic markers LC3 and p62 and (2) protein
aggregation marker TDP-43 in 53 subjects with pathologically diagnosed PM, IBM, and two intermediate T cell-
mediated inflammatory myopathies (polymyositis with COX-negative fibers and possible IBM). The percentage of
stained fibers was significantly higher in IBM than PM for all three immunostains, but the markers varied in
sensitivity and specificity. In particular, both LC3 and p62 were sensitive markers of IBM, but the tradeoff between
sensitivity and specificity was smaller (and diagnostic utility thus greater) for LC3 than for p62. In contrast, TDP-43
immunopositivity was highly specific for IBM, but the sensitivity of this test was low, with definitive staining present
in just 67% of IBM cases.
Conclusions: To differentiate IBM from PM, we thus recommend using a panel of LC3 and TDP-43 antibodies: the
finding of <14% LC3-positive fibers helps exclude IBM, while >7% of TDP-43-positive fibers strongly supports a
diagnosis of IBM. These data provide support for the hypothesis that disruption of autophagy and protein
aggregation contribute to IBM pathogenesis.
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Sporadic inclusion body myositis (IBM) is a common in-
flammatory myopathy that classically presents in older
individuals with proximal lower extremity and finger
flexor weakness; the clinical course is generally slow but
progressive and unresponsive to immunosuppressive
therapy, thus leading to significant disability. Histologi-
cally, IBM shows chronic myopathic changes in a back-
ground of T cell-rich endomysial inflammation [1-3]. In
addition, IBM is marked by the presence of large protein* Correspondence: Marta.Margeta@ucsf.edu
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reproduction in any medium, provided the oraggregates associated with rimmed vacuoles (RVs) –
cleared-out spaces surrounded by the basophilic granu-
lar material [1,3]. The pathogenesis of IBM is complex
and not fully understood. Based on the histopathologic
features of the disease, both degenerative and auto-
immune etiologies have been proposed, but no one mo-
lecular mechanism has been broadly accepted [1,3-7].
The pathologic diagnosis of IBM requires its differenti-
ation from two groups of disorders. First, IBM must be
distinguished from other muscle disorders with RVs;
these include hereditary inclusion body myopathies,
some limb-girdle muscular dystrophies, many distal my-
opathies, and drug-induced autophagic vacuolar myop-
athies. Generally, the distinction between sporadic IBMLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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IBM shows a prominent T cell-rich endomysial inflamma-
tory infiltrate and diffuse upregulation of major histocom-
patibility complex I (MHC-1) in muscle fibers; other
myopathies with RVs do not [1]. Second, IBM must be dis-
tinguished from polymyositis (PM), another T cell-rich in-
flammatory myopathy with diffuse MHC-1 upregulation.
Clinically, the distinction of PM from IBM is critical: the
two diseases show markedly different response to cortico-
steroid therapy, with PM usually significantly responsive
and IBM largely unresponsive to treatment. In contrast to
PM, IBM generally shows chronic myopathic features
(such as endomysial fibrosis and fiber size variation) and
RVs [1,3]. However, standard histologic methods can
visualize RVs only in the frozen tissue [1]; in addition, RVs
are often scarce [3,8]. Thus, the current pathologic criteria
for IBM are specific but not sensitive for diagnosis; in the
absence of supporting clinical information, a significant
fraction of IBM patients is misdiagnosed with chronic
polymyositis, leading to unnecessary steroid treatment.
Given the limitations of the current diagnostic criteria,
there has been substantial effort to identify an immuno-
histochemical marker for IBM with a higher sensitivity
than RVs. Since protein aggregation is considered central
to IBM pathogenesis, several groups have evaluated im-
munoreactivity for aggregation-prone proteins [including
amyloid-β, amyloid-β precursor protein, phosphorylated
neurofilament (SMI-31), ubiquitin, alpha-B crystallin,
and TAR-DNA binding protein-43 (TDP-43)] in IBM
specimens [9-13]. Many of these markers are specific
but not sensitive for IBM and, like RVs, are limited by
the scarcity of positive staining. For example, SMI-31
staining highlighted an average of 0.7% of fibers in IBM,
less than the percentage of fibers with RVs [13]. Cur-
rently, the most promising protein aggregation marker is
TDP-43: TDP-43 immunohistochemistry was positive in
21 of 27 cases (78%) of sporadic IBM in an initial study
[14] and 77% of cases in a further study [12]. Overall,
quantitation of TDP-43 has been variable and ranges
from an average of <1% to 23% muscle fibers in IBM
cases [10,15,16].
A different approach to finding a sensitive marker for
IBM is to look for markers related to removal of abnor-
mally aggregated proteins. In both animal [17] and hu-
man studies [18-20], RV formation has been linked to
the impairment of autophagy, a catabolic process that
targets cytoplasmic organelles and protein aggregates
for lysosomal degradation [21]. Autophagy impairment
leads to accumulation of autophagosomes, which can be
detected by immunohistochemistry for autophagy pro-
teins LC3 (microtubule-associated protein 1 light chain
3) and p62/SQSTM1; we have recently shown that im-
munostaining for either LC3 or p62 can replace electron
microscopy in the diagnosis of drug-induced autophagicvacuolar myopathies [18,22]. LC3 and p62 have also
been evaluated as markers of IBM. Temiz et al. have
reported that LC3 aggregates are present in most cases
of IBM and COX-negative polymyositis (PM-COX) and
absent in most cases of PM; however, a threshold for
deeming a case positive for each marker was not speci-
fied [12]. A second study found that more fibers were
positive for p62 than for TDP-43 in IBM, but did not
examine PM or other entities in the differential diagno-
sis [15]. The most complete study thus far evaluated
p62 and TDP-43 staining in IBM, possible IBM (pIBM),
and a small group (seven cases) of either PM or derm-
atomyositis (DM) [10]. An apparent difference in the
mean fraction of p62- and TDP-43-positive fibers was
demonstrated between IBM and PM/DM; however, stat-
istical analysis was not performed, and DM is usually
not in the pathologic differential diagnosis with IBM.
Though useful, these studies thus lack two critical ele-
ments. First, there has been no systematic quantification
of all three stains across the same set of specimens,
which would allow a better understanding of the role of
autophagy impairment and protein aggregation in IBM
pathogenesis. Second, almost none of these reports fo-
cused on the situation we consider most diagnostically
challenging; namely, distinguishing IBM from PM in cases
with atypical clinical history or incompletely developed
histologic features. In the current study, we therefore
undertake a quantitative and systematic study of LC3, p62,
and TDP-43 immunohistochemistry in a broad spectrum
of T-cell mediated inflammatory myopathies. We begin by
establishing the sensitivity and specificity of each marker
in the clear-cut cases of PM and IBM, then use these find-
ings to evaluate more challenging cases with intermediate
PM-COX and pIBM pathology.Methods
Ethics statement
Study design was reviewed and approved by the Univer-
sity of California San Francisco (UCSF) Committee on
Human Research (CHR). Given the non-invasive nature of
the study and a minimal potential for harm to study par-
ticipants, the informed consent requirement was waived
by the CHR. No individually identifiable patient data is
presented in this report.Objectives
The objective of this study was to determine (1) whether
quantitative immunohistochemistry for LC3, p62, and/or
TDP-43 can be used as a diagnostic tool to differentiate
IBM from PM and (2) whether these markers can help
classify intermediate forms of T cell-rich inflammatory
myopathies (PM-COX and pIBM; further defined in the
Participants section).
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To identify cases for the study, we performed a comput-
erized search of the UCSF neuropathology case database
spanning the interval between 1990 and 2012. Candi-
date cases (for which archival formalin-fixed, paraffin-
embedded [FFPE] tissue was available) were classified
into four groups (PM, PM-COX, pIBM, and IBM) by
consensus of two Board-certified neuromuscular pathol-
ogists (HSL and MM), who were blinded to the clinical
history and previous diagnoses. The classification was
made after review of all available original light micros-
copy slides; these generally included hematoxylin and
eosin (H&E) stain of the FFPE material; H&E, modified
trichrome, ATPase (pH 9.2), NADH reductase, SDH,
and COX stains of the frozen material; MHC-1 im-
munoperoxidase stain of the frozen material; and CD3,
CD20 and CD8 immunoperoxidase stains of either the
FFPE or frozen material. (All stains were not available in
all cases, and the minimal stain set considered sufficient
for classification included frozen section H&E [for all
cases] and COX stain [for PM and PM-COX cases].)
The diagnostic criteria used for classification are sum-
marized in Table 1; cases with mixed features (for ex-
ample, dermatomyositis/PM or dermatomyositis/IBM)
and cases with unusual morphologic findings (for
example, the presence of large lymphoid follicle-like in-
flammatory aggregates) were excluded. Clinical infor-
mation available for each case was reviewed following
initial histopathology classification, and a subset of
cases was excluded from further study due to theTable 1 Summary of consensus diagnostic criteria used for ca













Fiber invasionb Present Pr
Diffuse MHC-1 positivityb Present Pr
Endomysial fibrosisa None or mild None




Ragged red fibersb Absent Pr
Classic rimmed vacuolesa Absent A
Rimmed cracks or basophilic
granular debrisb
Absent A
a Main criteria (required for diagnosis / classification).
b Supporting criteria.
c Specimens with “moderate to severe fiber size variation” included the entire rang
than just two populations of normal-sized and atrophic fibers, as can be seen in PM
d For pIBM classification, presence of rimmed cracks (incomplete rimmed vacuoles;
of basophilic RV rim) was required in cases with moderate fibrosis but optional in cpresence of a concurrent disease (such as connective tis-
sue disorder, lymphoproliferative neoplasm, or AIDS)
that raised the possibility of secondary rather than pri-
mary inflammatory myopathy. Because approximately
two thirds of our muscle biopsies come from outside re-
ferring institutions and are accompanied by limited clin-
ical information, the clinical features were otherwise not
incorporated into diagnostic criteria. Given that group
assignment was based solely on morphologic features,
no attempt was made to match participants by age, sex,
or other demographic variables.
Procedures
Immunohistochemistry
Immunoperoxidase staining for LC3 (mouse monoclonal
antibody, clone 5F10, Nanotools; 1:100 dilution following
antigen retrieval) and p62/SQSTM1 (guinea pig polyclonal
antibody, Progen Biotechnik; 1:100 dilution following anti-
gen retrieval) was performed on FFPE tissue samples using
Ventana Benchmark XT automated slide preparation
system at the UCSF Brain Tumor Research Center Tissue
Core as described previously [18]. Immunoperoxidase
staining for TDP-43 (rabbit polyclonal antibody, Pro-
teintech Group, Chicago, IL) was performed on FFPE tis-
sue samples either manually (1:3000 antibody dilution; no
antigen retrieval) or using a Leica Bond automated slide
preparation system (1:1000 antibody dilution; antigen re-
trieval for 20 min in a buffer with pH = 6.0 and at a
temperature of up to 100°C); the two staining methods
produced essentially identical results.se classification
-COX pIBM IBM
esent Present Present









or mild Moderate to severe Moderate to severe
or mild Moderate to severec Moderate to severec
≥1% Any (generally >1%) Any (generally >1%)
esent Either (generally present) Either (generally present)
bsent Absent Present
bsent Presentd Either (generally present)
e of muscle fiber sizes (from atrophic to hypertropic; <5 to >100 μm) rather
.
Figure 5E, white arrowhead) or basophilic granular debris (material reminiscent
ases with severe fibrosis.
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Quantification was performed on immunostained FFPE
sections using a bright-field light microscope as de-
scribed previously [18], with the investigator blinded to
group assignment of each subject. Briefly, muscle fibers
containing inclusions, RVs, threads/skeins (in case of
TDP-43), or coarse sarcoplasmic puncta were counted
as positive, while fibers lacking such staining were counted
as negative. A total of 200 fibers/slide was counted in
specimens with abundant positivity, while a total of 600 fi-
bers/slide was counted in specimens with scarce or patchy
positivity (to reduce the sampling error).
Imaging
Images were taken with a DP72 digital camera on a
BX41 bright-field light microscope using cellSens Entry
1.6 software (all by Olympus) and were edited with
Adobe Photoshop CS5 Version 12.1.32.
Statistical methods
Data were analyzed with GraphPad Prism 6 statistical
software. For between-group comparison of demographic
variables, we used one-way ANOVA with post-hoc Tukey
test (age) or chi-square test (sex). LC3, p62, and TDP-43
immunopositivity data showed significantly different vari-
ances among groups; thus, between-group comparison
was performed by t-test with Welch’s correction or
Kruskal-Wallis one-way ANOVA on ranks. To calculate
diagnostic threshold values with optimal sensitivity and
specificity, receiver operating characteristic (ROC) analysis
was performed on the data from PM and IBM groups. All
tests were two-tailed with α=0.05.
Results
Demographics
Participant assignment to study groups was based solely
on morphologic criteria (see Methods and Table 1 for
details) and no attempt was made to match participants
by age, sex, or other demographic variables. As expected
based on the previous reports, the average age of PM
subjects (55.8 ± 12.0 y [mean ± SD]) was significantly
lower than the age of IBM subjects (68.9 ± 7.1 y; p<0.05)
but not significantly different from the ages of PM-COX
subjects (64.4 ± 9.7 y) or pIBM subjects (59.6 ± 14.1 y).
In addition, there was no significant difference in the
average age between PM-COX, pIBM, and IBM groups.
Sex distribution was not statistically different between
the four study groups (17% [PM] vs. 62% [PM-COX] vs.
63% [pIBM] vs. 50% [IBM] female; p = 0.07).
The level of plasma creatine kinase (CK) prior to bi-
opsy was available in the clinical record of 44 of 53 sub-
jects (Table 1). Given the incompleteness of the data
and variations in the reporting precision, statistical ana-
lysis of this parameter was not possible; however, CK >1000 U/L was present in the majority of subjects in the
PM group (10 of 12), half of subjects in the pIBM group
(7 of 14), and the minority of subjects in the other two
groups (1 of 9 subjects in the IBM group and 3 of 9 sub-
jects in the PM-COX group). The demographic and CK
level data for all subjects are shown in Table 2.
Classic PM and IBM
Immunohistochemistry for LC3, p62 and TDP-43 was
performed on FFPE tissue. (While antibodies can show
different antigen sensitivity on frozen and FFPE sections,
we have previously demonstrated that LC3 and p62 anti-
bodies used in this study perform similarly in both prep-
arations [18].) In PM samples, there was little or no
sarcoplasmic staining with any of the three antibodies
(Figures 1b-d; subject #10); however, p62 faintly stained
inflammatory cells (Figure 1c), while TDP-43 labeled the
majority of myofiber and lymphocyte nuclei (Figure 1d).
In some PM samples, rare fibers were LC3 and/or p62-
positive; when present, such staining was generally
coarsely punctate, with no labeling of large protein aggre-
gates or RVs (not shown). (Normal human skeletal muscle
shows no sarcoplasmic LC3 or p62 immunopositivity
[18].) In contrast, IBM samples contained many LC3-
and/or p62-positive fibers, typically showing coarse granu-
larity and/or staining of RV rims (Figures 1f-g; subject
#22); in addition, p62 often labeled sarcoplasmic protein
aggregates and inflammatory cells (Figure 1g). TDP-43
showed three patterns of sarcoplasmic staining in IBM
specimens (Figure 1h): large protein inclusions/aggregates
(arrows, Figure 1h), thread-like skeins (black arrowheads;
Figure 1h), and coarse granularity (seen in the background
of the fiber with other inclusions); the rim of RVs typically
was not labeled, and background nuclear staining was
generally preserved.
To statistically compare the degree of LC3-, p62- and
TDP-43-positivity between PM and IBM groups, we
quantified the percentage of fibers staining (%FS) on
each section. Data for individual subjects are shown in
Table 2; interestingly, the percentage of LC3- and p62-
positive fibers exceeded the percentage of fibers with
RVs in all IBM cases, while TDP-43 data were more vari-
able. The percentage of LC3-positive fibers was signifi-
cantly higher in the IBM group (25.3 ± 3.3%FS) than in
the PM group (4.4 ± 0.8%FS) (mean ± SEM, p<0.0001;
two-tailed t-test with Welch’s correction; Figure 2a).
Similar results were seen with p62 (IBM, 25.3 ± 4.3%FS;
PM, 7.2 ± 1.5%FS; mean ± SEM, p=0.001; Figure 2c) and
TDP-43 immunohistochemistry (IBM, 12.9 ± 3.5%FS;
PM, 1.0 ± 0.4%FS; mean ± SEM, p=0.006; Figure 2e).
ROC analysis showed that while all three immunohisto-
chemical tests effectively distinguished IBM from PM
specimens (p ≤ 0.001 for area under the ROC curve),
there were large differences in sensitivity and specificity
Table 2 Study subject characteristics
Subject ID Group CK level (U/L) Sex Age at diagnosis Rimmed vacuoles (%F) LC3 (%FS) p62 (%FS) TDP-43 (%FS)
1 PM 1,092 M 59 0.0 5.7 5.5 1.2
2 PM “1,000 s” M 85 0.0 6.0 10.0 0.5
3 PM 2,405 F 51 0.0 4.0 0.3 5.5
4 PM 1231 M 65 0.0 2.5 3.7 1.2
5 PM 1,497 M 47 0.0 1.7 11.0 0.2
6 PM 10,000 M 42 0.0 11.3 10.2 0.2
7 PM 477 F 66 0.0 3.8 4.0 0.5
8 PM 6,000 to 19,000 M 50 0.0 4.0 7.5 1.2
9 PM 3,000 M 59 0.0 6.7 8.3 0.8
10 PM 834 M 53 0.0 2.7 19.2 0.3
11 PM 2,300 M 43 0.0 2.7 4.0 0.2
12 PM 1,000 to 4,000 M 50 0.0 2.0 2.8 0.2
13 IBM 515 ( 1 y before biopsy) F 64 2.7 31.0 18.5 8.5
14 IBM 5,201 F 75 1.2 19.5 18.0 1.0
15a IBM 700 F 57 1.0 24.0 20.0 12.5
16a IBM 444 M 62 4.3 29.5 59.5 40.5
17 IBM 547 M 77 2.5 15.5 16.5 9.0
18 IBM NA F 74 1.5 16.0 9.2 2.8
19 IBM 235 (5 y before biopsy) F 73 3.0 34.0 32.5 16.0
20a IBM 576 to 732 F 69 4.5 48.5 43.5 27.5
21 IBM NA M 75 3.0 11.0 22.5 18.5
22 IBM 900 M 59 2.2 33.5 36.0 16.0
23a IBM 700 M 66 0.7 9.0 15.0 1.8
24 IBM NA M 76 0.5 32.5 12.0 0.2
25 PM-COX NA M 54 0.0 2.7 4.8 1.3
26 PM-COX 121 F 71 0.0 3.7 7.7 4.7
27 PM-COX 802 F 55 0.0 6.0 6.3 0.2
28 PM-COX 1,254 to 2,093 F 85 0.0 10.0 4.7 0.5
29a PM-COX 395 M 75 0.0 13.7 13.8 1.0
30 PM-COX 174 to 229 M 54 0.0 3.8 8.0 1.0
31 PM-COX NA F 76 0.0 4.3 8.8 4.2
32 PM-COX 2,000 to 3,000 F 58 0.0 3.3 1.5 0.7
33a PM-COX NA M 59 0.0 15.5 22.5 16.0
34 PM-COX NA F 63 0.0 16.5 28.5 4.5
35a PM-COX 871 M 64 0.0 47.5 30.5 0.5
36 PM-COX 74,600 F 58 0.0 2.3 2.3 0.2
37 PM-COX 339 to 789 F 65 0.0 4.7 3.0 2.5
38 pIBM 6,500 F 42 0.0 3.8 12.8 1.2
39 pIBM 6,000 to 12,000 F 58 0.0 33.0 32.0 0.5
40 pIBM 802 F 71 0.0 5.3 2.5 0.3
41 pIBM 7,090 F 55 0.0 16.5 34.5 0.7
42 pIBM 74,000 F 61 0.0 18.5 10.5 4.2
43a pIBM 871 M 62 0.0 25.5 10.5 6.5
44 pIBM 4,580 F 30 0.0 74.0 58.5 1.3
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Table 2 Study subject characteristics (Continued)
45 pIBM NA F 75 0.0 15.5 5.5 0.5
46a pIBM 840 M 64 0.0 17.0 21.0 12.0
47 pIBM 10,000 M 53 0.0 16.0 15.3 1.2
48 pIBM 864 F 44 0.0 6.7 4.5 0.0
49 pIBM 600 F 83 0.0 24.7 2.5 0.3
50 pIBM 293 M 68 0.0 7.3 4.8 1.3
51 pIBM 6,000 F 50 0.0 21.5 17.0 0.8
52a pIBM 222 (4 y after biopsy) M 79 0.0 17.5 22.5 3.3
53 pIBM NA M 58 0.0 7.2 2.5 2.5
a Classic IBM history.
NA not available, %FS the percentage of fibers staining, %F the percentage of fibers with rimmed vacuoles.
Figure 1 PM and IBM staining patterns. A representative case of PM (a-d; subject #10) shows endomysial lymphocytic inflammation and
muscle fiber invasion but no chronic myopathic features (a; H&E stain of the frozen material). There is no significant sarcoplasmic staining with
LC3 (b), p62 (c), or TDP-43 (d), but TDP-43 stain highlights a subset of myofiber and inflammatory cell nuclei (internal positive control), while p62
faintly stains a subset of lymphocytes. A representative case of IBM (e-h, subject #22) shows endomysial inflammation accompanied by moderate
to severe endomysial fibrosis, muscle fiber size variation, and RVs (white arrowhead) (e; H&E, frozen material). Staining for LC3 (f) and p62 (g)
highlights RV rims; p62 also labels RV-associated protein aggregates (arrow) and scattered lymphocytes. TDP-43 immunostain (h) labels
sarcoplasmic threads/skeins (black arrowheads), large protein aggregates (arrows), and coarse background puncta. Scale bars, 50 μM for a-c and
e-g; 20 μM for d and h.
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Figure 2 Quantification of LC3, p62, and TDP-43 positive fibers in the PM and IBM groups. The percentage of LC3- (a), p62- (c), and TDP-
43-positive fibers (e) was significantly higher in the IBM group than the PM group. Each subject is represented with a symbol; the open symbols
indicate subjects with known IBM clinical presentation. The unbroken lines designate group means, while dotted lines mark 100% sensitivity and
100% specificity cutoffs for each marker derived from ROC analysis. ****, p < 0.0001; **, p < 0.01. ROC analysis (b, d, and f) shows that
quantitative immunohistochemistry for each of the three markers successfully differentiates IBM from PM subjects (p ≤ 0.001), although with
varying tradeoffs between specificity and sensitivity. Of the three markers examined, only TDP-43 (f) failed to reach 100% sensitivity threshold,
indicated by the dotted line in (f).
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particular, both LC3 and p62 were sensitive markers of
IBM, but the tradeoff between sensitivity and specificity
was smaller for LC3 (100% specificity and 83% sensitivity
for IBM using a threshold value of 13.4%FS) than for
p62 (100% specificity and 50% sensitivity for IBM using
a threshold value of 19.6%FS). TDP-43 immunopositivity
was a highly specific marker of IBM, but the sensitivity
of this test was low: a threshold value of 7%FS excludedall PM cases but captured only 67% (8 of 12) of IBM
cases. In fact, the sensitivity of TDP-43 immunohisto-
chemistry did not reach 100% even when the threshold
value was set at the very low value of 0.3%FS (Figure 2f ).
Complete ROC analysis data are shown in Additional
file 1: Table S1 (LC3), Additional file 2: Table S2 (p62),
and Additional file 3: Table S3 (TDP-43).
Four of 12 subjects in the IBM group (and no subjects
in the PM group) had clinical presentation classic for
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and CK lower than 1000 U/L) and would thus be classified
as “definite IBM” using the European Neuromuscular
Center (ENMC) criteria [23]; these subjects are designated
by superscript a in Table 1 and by empty symbols in
Figure 2. (The other 8 subjects in the IBM group either
had atypical clinical presentation or, more commonly,
lacked sufficient clinical information to make definitive as-
sessment either way.) Interestingly, LC3, p62 and TDP-43
immunopositivities were not uniformly high in muscle bi-
opsies from the 4 subjects with classic IBM history; rather,
they showed a large range of labeling that spanned the
entire spectrum of %FS values seen in the IBM group,
with 3 of 4 subjects meeting or exceeding the 100%
specificity threshold set for each of the three markers
(Figures 2a, 2c, and 2e).
Taken together, these data indicate that (1) all three
immunohistochemical markers effectively distinguish the
IBM subject group from the PM subject group; (2) LC3
immunohistochemistry shows the best tradeoff between
sensitivity and specificity as a diagnostic test applied to
individual biopsies to confirm (or exclude) the diagnosis
of IBM; and (3) given the high specificity of TDP-43 im-
munohistochemistry for IBM, TDP-43 immunopositivity
confers additional support for a diagnosis of IBM andFigure 3 PM-COX staining patterns. PM-COX cases were histologically si
lack of well-developed chronic myopathic features (a and f; H&E, frozen ma
material; COX-negative fibers are marked by asterisks). The majority of PM-C
sarcoplasmic labeling for LC3 (c), p62 (d), or TDP-43 (e). In a subset of sam
RV rims and small protein aggregates (i), while TDP-43 labeled sarcoplasmi
subject #33; scale bar, 50 μM.can thus be helpful in cases that have atypical clinical
presentation or lack adequate clinical information.
PM-COX
PM-COX shows worse response to steroid therapy than
classic PM and is thus thought to represent either a
form of progression from PM toward IBM or an early
stage of IBM with incompletely developed pathologic fea-
tures [8,12,24]. To evaluate whether immunohistochemis-
try for LC3, p62 and/or TDP-43 can distinguish PM-COX
from classic PM and/or IBM, we evaluated 13 specimens
with histologic features of polymyositis but ≥1% COX-
negative fibers (for full diagnostic criteria, see Table 1).
The majority of PM-COX specimens showed only min-
imal LC3, p62 or TDP-43 immunopositivity and thus re-
sembled PM more than IBM; a representative biopsy from
this subgroup (subject #37) is shown in Figures 3a-e.
However, a few PM-COX specimens showed a significant
degree of LC3-, p62-, and TDP-43 immunostaining, re-
sembling classic IBM (see Table 2 for quantification); the
single biopsy positive for all three markers (subject #33) is
shown in Figures 3f-j.
Quantitative comparison of the entire PM-COX group
with the PM and IBM groups is shown in Figure 4. For
all three markers, there was no statistically significantmilar to classic PM, with endomysial inflammation, fiber invasion, and
terial), but with ≥ 1% COX-negative fibers (b and g; COX stain, frozen
OX samples (designated PM-COX low) showed no significant
ples (designated PM-COX high), LC3 labeled RV rims (h), p62 labeled
c skeins and large protein aggregates (arrows; j). a-e, subject #37, f-j,
Figure 4 Quantification of LC3, p62, and TDP-43 positive fibers
in the PM-COX group. The percentage of LC3- (a) and p62-positive
fibers (b) was significantly lower in the PM-COX group than in the
IBM group, but similar to the PM group. With TDP-43 (c), there was
no statistically significant difference between the PM-COX group
and either the PM or IBM group. Each subject is represented with a
symbol; the open symbols indicate subjects with known IBM clinical
presentation. The unbroken lines designate group medians, while
the dashed lines mark 100% sensitivity and 100% specificity cutoffs
for each marker (derived from the ROC analysis shown in Figure 2).
**, p < 0.01.
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LC3, 4.7%FS; p62, 7.7%FS; TDP43, 1.0%FS) and the PM
group (median: LC3, 3.9%FS; p62, 6.5%FS; TDP43, 0.5%
FS) (p>0.05, Kruskal-Wallis ANOVA on ranks). In con-
trast, the fraction of LC3- and p62-postive fibers (but
not TDP-43-positive fibers) was significantly lower in
the PM-COX group than in the IBM group (median:
LC3, 26.8%FS; p62, 19.3%FS; TDP43, 10.8%FS) (p<0.01
for LC3 and p62, p>0.05 for TDP-43). Interestingly,
there was no correlation between the fraction of ragged
red and COX-negative fibers and the degree of LC3,
p62, and TDP-43 immunopositivity (Additional file 4:
Table S4).
Three of 13 subjects that showed PM-COX pathology
had clinical presentations classic for IBM and would
thus be classified as “probable IBM” using the ENMC
criteria. (As with the IBM group, the other 10 subjects
either had clinical presentation more consistent with PM
or, more frequently, lacked sufficient clinical information
to make definitive assessment either way.) Among the 3
subjects with IBM presentation (designated by open
symbols in Figure 4), all 3 subjects exceeded the IBM
100% specificity threshold for LC3, 2 subjects exceeded
the IBM 100% specificity threshold for p62, and 1 sub-
ject (#33, shown in Figures 3f-j) exceeded the IBM 100%
specificity threshold for TDP-43. While the interpret-
ation of this finding is limited by the low number of
subjects with well-defined clinical history in our study
set, these data suggest that, in cases with PM-COX hist-
ology, LC3 immunopositivity may identify the patients
that are in the early stages of IBM and thus unlikely to
respond to immunosuppressive therapy.
Taken together, the data indicate that the PM-COX
group is heterogeneous but overall shows a low degree
of LC3 and p62 immunopositivity more similar to classic
PM than classic IBM. Nonetheless, a subset of PM-COX
subjects with clinical presentation suggestive of IBM
showed high labeling for autophagic markers LC3 and
p62, but not for aggregation marker TDP-43; this finding
supports the hypothesis that autophagy impairment oc-
curs early and accumulation of misfolded proteins late
in IBM pathogenesis [12,25].
pIBM
Current diagnostic criteria for IBM require identification
of RVs (Figure 1e, white arrowhead) in the context of a
chronic T-cell rich inflammatory myopathy; however,
many biopsies lack RVs while meeting all other diagnos-
tic criteria for IBM and are thus currently diagnosed as
possible IBM (pIBM). [Sixteen specimens included in
the pIBM group in our study lacked well-developed RVs
but showed either severe chronic myopathic features or
moderate chronic myopathic features together with baso-
philic granular debris and “rimmed cracks” (incompletely
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arrowhead); for full diagnostic criteria, see Table 1.] Given
that the lack of RVs in the majority of pIBM cases likely
represents a sampling error rather than a true finding, we
hypothesized that the fraction of fibers positive for au-
tophagic markers LC3 and p62 (but not necessarily pro-
tein aggregation marker TDP-43) would be high in pIBM
specimens. Indeed, most pIBM biopsies showed a high de-
gree of LC3 and p62 immunopositivity and a low degree
of TDP-43 immunopositivity; a representative example is
shown in Figures 5a-d (subject #52). A subset of pIBM
cases, however, was essentially immunonegative for all
three markers examined; a representative example is
shown in Figures 5e-h (subject #51). Interestingly, when
pIBM subjects were stratified by CK level with a cutoff
value of 1000 U/L, both low and high CK subgroups
showed a similar range of labeling for LC3 and TDP-43;
in contrast, p62 labeling was significantly lower in pIBM
subjects with low CK level (Additional file 5: Figure S1).
Quantitative comparison of the entire pIBM group
with the PM and IBM groups is shown in Figure 6. TheFigure 5 pIBM staining patterns. pIBM cases were histologically similar t
moderate-severe chronic myopathic features, but without classic RVs (a an
present in a subset of specimens. The majority of pIBM samples (designate
TDP-43 immunopositivity was less commonly observed (d; arrow marks a s
fibers showed dense coarse puncta and rare RV-like structures (black arrow
or no labeling was seen with all three markers (f-h). a-d, subject #52, e-h, sfraction of LC3-positive fibers was significantly higher in
the pIBM group (median, 16.8%FS) than in the PM group
(median, 3.9%FS; p<0.01), but not significantly different
from that observed in the IBM group (median, 26.8%FS;
p>0.05, Kruskal-Wallis ANOVA on ranks). p62 immuno-
histochemistry showed a large spread of %FS values in the
pIBM group (median, 11.7%FS), with no significant differ-
ence from either the PM group (median, 6.5%FS; p>0.05)
or the IBM group (median, 19.3%FS; p>0.05). Finally,
TDP-43 immunopositivity was low in all but one pIBM
subject; thus, the fraction of TDP-43-immunopositive fi-
bers in the pIBM group (median, 1.2%FS) was significantly
lower than in the IBM group (median, 10.8%FS; p<0.05)
and not significantly different from that observed in the
PM group (median, 0.5%FS; p>0.05).
Three of 16 subjects in the pIBM group had clinical
presentation classic for IBM and would thus be classified
as “probable IBM” using the ENMC criteria. (As with
the PM-COX and IBM groups, the other 13 subjects ei-
ther had clinical presentation more consistent with PM or,
more commonly, lacked sufficient clinical information too classic IBM, with endomysial inflammation, fiber invasion, and
d f; H&E, frozen material); “rimmed cracks” (white arrowhead in e) were
d pIBM high) showed well-developed labeling for LC3 (b) and p62 (c);
ingle TDP-43 positive fiber). In the example shown (subject #52), many
head in b). In a smaller subset of samples (designated pIBM low), little
ubject #51; scale bar, 50 μM.
Figure 6 Quantification of LC3, p62, and TDP-43 positive fibers
in the pIBM group. The percentage of LC3-positive fibers (a) was
significantly higher in the pIBM group than in the PM group, but
similar to the IBM group. With p62 (b), there was no statistically
significant difference between the pIBM group and either the PM or
IBM group. The percentage of TDP-43-positive fibers (c) was
significantly lower in the pIBM group than in the IBM group, but
similar to the PM group. Each subject is represented with a symbol;
the open symbols indicate subjects with known IBM clinical
presentation. The unbroken lines designate group medians, while
the dotted lines mark 100% sensitivity and 100% specificity cutoffs
for each marker (derived from the ROC analysis shown in Figure 2).
**, p < 0.01; *, p < 0.05.
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pIBM subjects with IBM clinical history (designated by
open symbols in Figure 6), all 3 subjects exceeded the
IBM 100% specificity threshold for LC3, 2 subjects
exceeded the IBM 100% specificity threshold for p62, and
only 1 subject exceeded the IBM 100% specificity
threshold for TDP-43. These results are reminiscent of
those observed in the 3 PM-COX subjects with clinical
features of IBM, again consistent with the notion that
LC3 immunopositivity represents an early and TDP-43
immunopositivity a late marker of IBM.
Discussion
IBM differs from other inflammatory myopathies by its
lack of responsiveness to immunosuppressive therapy
and poor prognosis. Thus, accuracy of pathologic diag-
nosis is critical, particularly when a patient is not clinic-
ally evaluated by a neuromuscular neurology specialist;
however, differentiation of IBM from PM (which shows
a significant histologic overlap) can be difficult. In this
study, we quantitatively evaluated three immunohisto-
chemical markers, LC3, p62 and TDP-43, for their diag-
nostic utility in differentiating IBM from PM and
intermediate T cell-rich inflammatory myopathies, PM-
COX and pIBM.
Several earlier studies have examined LC3, p62 or TDP-
43 staining in the setting of IBM; however, no single work
quantitatively compared all three markers on the same set
of well-defined specimens. Of the three markers, TDP-43
has been the best studied: similar to our results, other au-
thors have found that it stains most but not all cases of
IBM [12,14,16]. Quantitative studies of TDP-43 staining
(based on immunofluorescence or immunoperoxidase la-
beling of frozen sections) have been somewhat variable,
with mean %FS in IBM ranging from <1% to 23%
[10,15,16]; our results (based on immunoperoxidase label-
ing of FFPE sections) are very similar (mean %FS, 13%;
67% sensitivity using 7% labeling cutoff and 90% sensitiv-
ity using 1% labeling cutoff), indicating that the two ap-
proaches give comparable results. Quantitative studies of
p62 and LC3 have been less frequent, and no study has
quantitatively compared the two markers we found the
most useful: LC3 and TDP-43.
In our study, LC3, p62, and TDP-43 all effectively dis-
tinguished the IBM subject group from the PM subject
group; however, LC3 immunohistochemistry showed the
best tradeoff between sensitivity and specificity for IBM
as a diagnostic test applied to an individual case (100%
specificity and 83% sensitivity for IBM using a threshold
value of 13.4%FS; Figure 2a). p62 staining was qualitatively
similar to LC3 staining, consistent with the idea that accu-
mulation of either LC3-labeled autophagosomes or p62-
positive aggregates can serve as a marker of autophagic
flux inhibition [26]. However, p62 staining showed a larger
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staining (100% specificity and 50% sensitivity for IBM
using a threshold value of 19.6%FS; Figure 2c). Interest-
ingly, both LC3 and p62 labeled coarse sarcoplasmic
puncta and the rim of RVs, suggesting that RVs are
delimited by built-up unprocessed autophagosomes.
The TDP-43 staining pattern, in contrast, was both
qualitatively and quantitatively unique. Like LC3 and
p62, TDP-43 staining was often positive in coarse sarco-
plasmic puncta. Unlike LC3 and p62, however, TDP-43
labeled sarcoplasmic skeins and large protein aggregates
(which were largely LC3- and p62-negative) and did not
label the RV rim (which was typically LC3- and p62-
positive). While TDP-43 staining was detectable in only
67% of our IBM cases (using 7%FS cutoff ), it was highly
specific for IBM in the setting of a T cell-rich inflamma-
tory myopathy, with essentially no staining in 11 of
12 PM biopsies. (In contrast, TDP-43 immunohisto-
chemistry is positive in other myopathies with RVs
[14,27] and thus does not differentiate sporadic IBM
from hereditary inclusion body myopathies.) Based on
these findings, we therefore suggest that the most useful
immunohistochemical approach to differentiate IBM
from PM in a muscle biopsy is to use a panel of LC3
and TDP-43 antibodies: a cutoff of <14%FS LC3 helps
rule out IBM, while >7%FS TDP-43 strongly supports a
diagnosis of IBM. Because >7%FS TDP-43 is highly spe-
cific for IBM, TDP-43 immunohistochemistry can be
particularly useful in cases with limited or atypical clin-
ical history. Importantly, because we optimized all im-
munohistochemical stains for FFPE tissue, this method
enables diagnosis of IBM even in situations when frozen
tissue is not available.
To determine whether immunopositivity for LC3, p62
and/or TDP43 provides additional information in diag-
nostically challenging cases, we evaluated two intermedi-
ate T cell-rich inflammatory myopathies – PM-COX and
pIBM. PM-COX has features of both PM (the absence
of chronic myopathic features and RVs) and IBM (the
presence of COX-negative fibers). This group, designated
“PM-Mito” or “PM/IBM” in some earlier studies, was
shown to respond less well to steroid therapy than clas-
sic PM [8,12,24]. Our PM-COX group showed a low%FS
for LC3 and p62 (median of 4.7%FS and 7.7%FS, respect-
ively) that was more similar to the PM group (median of
3.9%FS and 6.5%FS) than to the IBM group (median of
26.8%FS and 19.3%FS). This LC3 finding is in apparent
contrast to the work of Temiz et al., who showed that
87% of their PM-Mito cases were positive for LC3 [12].
We reconcile this apparent discrepancy by noting that
all of our PM-COX cases showed at least small amount
of positivity for LC3; however, %FS LC3 for IBM was
much greater. Since the findings of Temiz et al. are not
quantitative, the two results may well be the same,highlighting the additional information obtained by quan-
tifying %FS rather than using a binary system of positive
versus negative staining. An alternative possibility is that
all of the PM-Mito cases in the study by Temiz et al. had
clinical features of IBM; our PM-COX cases that met
“probable IBM” ENMC criteria also showed high degree
of LC3 immunopositivity (open symbols in Figure 4a; see
below for further discussion). Like PM-COX biopsies,
pIBM biopsies had features of both PM (the absence of
RVs) and IBM (the presence of chronic myopathic fea-
tures), but were histologically closer to the IBM end of the
spectrum. The pIBM group as a whole showed a high %FS
for LC3 (median, 16.8%FS) and a low %FS for TDP-43
(median, 1.2%FS), consistent with the idea that the major-
ity of pIBM cases represent an early stage of IBM with in-
completely developed pathologic features.
A clear limitation of our work is that, due to our role
as a neuropathology referral center, the clinical informa-
tion was incomplete for the majority (~ 2/3) of our study
subjects. However, a subset of biopsies from clinically
well-worked up subjects with classic IBM presentation
highlights a few trends that warrant further study. The
four (of 12) subjects in the IBM group that met “definite
IBM” ENMC criteria showed a large range of staining
that spanned the entire spectrum of IBM %FS values,
with 3 of 4 subjects meeting or exceeding the 100% spe-
cificity threshold set for each of the three markers. In
addition, 3 (of 13) subjects with PM-COX pathology and
3 (of 16) subjects with pIBM pathology met “probable
IBM” ENMC criteria; all 6 of these subjects (100%) met
or exceeded the >14%FS of LC3 threshold set for sensitive
diagnosis of IBM. While limited by small sample size,
these data suggest that >14%FS LC3 immunopositivity
might be useful as a cutoff value for patients that are un-
likely to respond to immunosuppressive therapy.
One model of IBM pathogenesis suggests that cyto-
plasmic protein accumulation occurs in a stepwise
fashion, with impairment of autophagic flux (detected
through LC3 and p62 accumulation) occurring first and
aggregation of TDP-43 and other misfolded proteins oc-
curring later [12,25]. Collectively, our results are in
agreement with this model; however, a conclusive evi-
dence for this sequence of events would require a posi-
tive correlation between the length of symptoms and
the degree of LC3- and TDP-43-immunopositivity or evi-
dence of progression from LC3-only to combined LC3
and TDP-43-immunopositivity in serial biopsies from the
same patients. The presence of ragged red and COX-
negative fibers in both PM-COX and IBM biopsies is con-
sistent with a possible involvement of impaired mitophagy
(mitochondrial autophagy) in these diseases. However, the
degree of LC3, p62, and TDP-43 staining did not correlate
with the percentage of COX-negative or ragged red fibers
in our PM-COX specimens (Additional file 4: Table S4),
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autophagy impairment in the IBM progression. Thus,
many questions regarding IBM pathogenesis, including
the precise role of autophagy and inflammation as well as
the apparent chronologic sequence of particular protein
accumulation, remain to be answered.
Strengths and limitations
The major strengths of the current study are (1) the
focus on a differential diagnosis (PM-IBM spectrum of T
cell-rich inflammatory myopathies) that is frequently en-
countered in everyday muscle pathology practice; (2) the
use of well-defined pathologic criteria for PM and IBM;
(3) the inclusion of two intermediate conditions, PM-
COX and pIBM, with equally well defined pathologic
criteria; (4) the quantitative study design, which enabled
calculations of sensitivity and specificity values for differ-
ent diagnostic thresholds, and (5) the evaluation of three
different markers across the same specimen set, enabling
direct comparison of their sensitivity and specificity for
IBM diagnosis. The major limitations are (1) the incom-
pleteness of clinical record for approximately two thirds
of our subjects, whose biopsies were received from out-
side institutions by our referral practice; and (2) the lack
of clinical follow-up information for the same subset of
subjects.
Conclusion
In summary, we showed that quantitative immunohisto-
chemistries for autophagic marker LC3 and protein ag-
gregation marker TDP-43 can be useful ancillary tools
for pathologic differentiation of PM from IBM and pos-
sible IBM precursor conditions, PM-COX and pIBM. By
reducing the number of cases with equivocal diagnosis,
particularly in a common setting of limited clinical in-
formation and/or suboptimally processed specimen
lacking the frozen tissue, the widespread use of these
immunostains has the potential to reduce the number
of patients receiving inappropriate treatment.
Additional files
Additional file 1: Table S1. LC3 immunohistochemistry: sensitivity and
specificity for IBM diagnosis at different cutoff values (from ROC analysis).
Additional file 2: Table S2. p62 immunohistochemistry: sensitivity and
specificity for IBM diagnosis at different cutoff values (from ROC analysis).
Additional file 3: Table S3. TDP-43 immunohistochemistry: sensitivity
and specificity for IBM diagnosis at different cutoff values (from ROC
analysis).
Additional file 4: Table S4. Percentage of COX-negative and ragged
red fibers in PM-COX group; LC3, p62, and TDP-43 data for the same
subjects are included for comparison.
Additional file 5: Figure S1. Comparison of the degree of LC3, p62,
and TDP-43 immunopositivity between pIBM subjects with the low and
high CK level. 14 pIBM subjects with known CK level (Table 2) werestratified into low CK subgroup (CK ≤ 1000 U/L) and high CK subgroup
(CK > 1000 U/L). The percentage of LC3- (a) and TDP-43-positive fibers (c)
was not significantly different between the two pIBM subgroups, while
the percentage of p62-positive fibers was significantly lower in the low
CK pIBM subgroup than the high CK pIBM subgroup (b). Each subject is
represented with a symbol; the open symbols indicate subjects with
known IBM clinical presentation. The unbroken lines designate group
means, while dotted lines mark 100% sensitivity and 100% specificity
cutoffs for each marker derived from ROC analysis. *, p < 0.05.
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